Dr. Asim Abdel-Mageed
Zimmermann Endowed Professor
Areas of Expertise
Biography
Dr. Abdel-Mageed received a D.V.M. from Sudan, M.S. and Ph.D. degrees in molecular physiology/toxicology from Kansas State University. In 1996, Dr. Abdel-Mageed became a research instructor of pharmacology at Tulane University School of Medicine, continuing his training in molecular cancer pharmacology. He studied genes associated with breast cancer cell growth and their interaction with nuclear transcription factors to mediate mitogenic responses. In 1997, Dr. Abdel-Mageed joined the faculty as an Assistant Professor of Urology, and the founding director of the Molecular Oncology Research in the Department of Urology. He then moved through the ranks to Professor of Urology and a Zimmermann Endowed Professor of Cancer Research at Tulane Cancer Center. In addition, Dr. Abdel-Mageed holds adjunct faculty positions in the Department of Pharmacology, Graduate Program in Biomedical Sciences and Center for Stem Cell Research and Regenerative Medicine. Dr. Abdel-Mageed research has been continuously supported by multiple grants from the National Cancer Institute (NCI) and the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), US Department of Defense (DoD), and the American Cancer Society (ACS). Dr. Abdel-Mageed received numerous awards during his academic career, and his research is marked with track record of over 85 peer-reviewed publications and more than 150 invited lectureships and presentations at national and international meetings. Dr. Abdel-Mageed has mentored and trained over 50 junior faculty, graduate students urology residents and postdoctoral fellows, and many international scholars during his tenure at Tulane. Currently, Dr. Abdel-Mageed is a standing member of the NIH/TME Study Section and has served on several study sections and review panels, including NIH, DOD and ASC as well as a number of international grant review panels (e.g. Qatar National Foundation, Italian Academy of Sciences, Singapore Medical Research Council). Currently, Dr. Abdel-Mageed is serving on the steering committee of the NIH Extracellular RNA Communication Consortium (ERCC) and the Vesicle Isolation and Function (VIF) subgroup of the ERCC. Dr. Abdel-Mageed has abroad background in molecular and cellular biology, underlying mechanisms, and molecular determinants of prostate cancer (PC) progression, racial disparity and tumor exosome-stem cell axis in mediating PC metastatic clonal expansion.
Education
Kansas State University
Kansas State University
University of Khartoum
Links
Articles
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes
2014
Emerging evidence suggests that mesenchymal stem cells (MSCs) are often recruited to tumor sites but their functional significance in tumor growth and disease progression remains elusive. Herein we report that prostate cancer (PC) cell microenvironment subverts PC patient adipose-derived stem cells (pASCs) to undergo neoplastic transformation.
High circulating estrogens and selective expression of ERβ in prostate tumors of African Americans: Implications for racial disparity of prostate cancer
2013
Although estrogen receptor beta (ERβ) has been implicated in prostate cancer (PCa) progression, its potential role in health disparity of PCa remains elusive. The objective of this study was to examine serum estrogens and prostate tumor ERβ expression and examine their correlation with clinical and pathological parameters in African American (AA) versus Caucasian American (CA) men.
PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth
2013
Although a relationship between PDZK1 expression and estrogen receptor (ER)-α stimulation has been suggested, the nature of such a connection and the function of PDZK1 in breast cancer remain unknown. Human tissue microarrays (cancer tissue: 262 cores; normal tissue: 87 cores) and breast cancer cell lines were used to conduct the study. We show that PDZK1 protein expression is tightly correlated with human breast malignancy, is negatively correlated with age and had no significant correlation with ER-α expression levels.
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways
2013
Although a wide spectrum of inhibitors of the MEK/ERK and PI3K/AKT pathways have been discovered and entered clinical trials, the effects of their individual use in thyroid cancer were often disappointing. We hypothesized that dual targeting of these two pathways would be a safe and effective strategy against aggressive thyroid cancers.
Adipose tissue derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction
2012
Porcine small intestinal submucosa (SIS) has been widely used in tunica albuginea (TA) reconstructive surgery. Adipose tissue-derived stem cells (ADSCs) can repair damaged tissue, augment cellular differentiation, and stimulate release of multiple growth factors. The aim of this rat study was to assess the feasibility of seeding ADSCs onto SIS grafts for TA reconstruction.
